Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002288 · ClinicalTrials.gov registry record · NA
The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002288: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002288 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002288, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To assess the efficacy of Retrovir (AZT) therapy in the treatment of HIV Ab positive persons with impairments in neuropsychological functioning. To assess the safety, virologic, and immunologic effects of AZT therapy in HIV Ab positive persons with neuropsychological impairment but minimal other symptomatology.
Interventions
- DRUG Zidovudine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002288 record still lists
NCT00002288 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Zidovudine is the first listed.
NCT00002288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002288 about?
NCT00002288 is a clinical study titled "The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System". To assess the efficacy of Retrovir (AZT) therapy in the treatment of HIV Ab positive persons with impairments in neuropsychological functioning. To assess the safety, virologic, and immunologic effects of AZT therapy in HIV Ab positive persons with neuropsychological impairment but minimal other sym...
What is the current status of trial NCT00002288?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002288?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00002288?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.